BG102837A - Среда за култивиране на клетки от бозайници - Google Patents

Среда за култивиране на клетки от бозайници Download PDF

Info

Publication number: BG102837A
Authority: BG; Bulgaria
Prior art keywords: cells; culture medium; hepatocytes; hbm; cell
Prior art date: 1996-03-18

Application number

BG102837A

Other languages

Bulgarian (bg)

English (en)

Inventor

Geoffrey Block

Original Assignee

University Of Pittsburgh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-18

Filing date

1998-10-12

Publication date

1999-05-31

1998-10-12 Application filed by University Of Pittsburgh filed Critical University Of Pittsburgh

1999-05-31 Publication of BG102837A publication Critical patent/BG102837A/bg

Links

241000124008 Mammalia Species 0.000 title claims abstract 4
210000003494 hepatocyte Anatomy 0.000 claims abstract description 190
210000004027 cell Anatomy 0.000 claims abstract description 179
230000009668 clonal growth Effects 0.000 claims abstract description 13
238000012423 maintenance Methods 0.000 claims abstract description 6
239000002609 medium Substances 0.000 claims description 78
102100021866 Hepatocyte growth factor Human genes 0.000 claims description 62
102000009024 Epidermal Growth Factor Human genes 0.000 claims description 55
239000001963 growth medium Substances 0.000 claims description 52
238000000034 method Methods 0.000 claims description 38
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 35
WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 claims description 34
230000012010 growth Effects 0.000 claims description 33
239000003102 growth factor Substances 0.000 claims description 33
230000014509 gene expression Effects 0.000 claims description 30
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 29
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 claims description 28
108010088751 Albumins Proteins 0.000 claims description 24
102000009027 Albumins Human genes 0.000 claims description 24
102000006747 Transforming Growth Factor alpha Human genes 0.000 claims description 24
101800004564 Transforming growth factor alpha Proteins 0.000 claims description 24
239000006143 cell culture medium Substances 0.000 claims description 23
238000000338 in vitro Methods 0.000 claims description 23
210000004185 liver Anatomy 0.000 claims description 22
230000035755 proliferation Effects 0.000 claims description 21
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 20
238000012546 transfer Methods 0.000 claims description 20
108090000623 proteins and genes Proteins 0.000 claims description 19
230000004663 cell proliferation Effects 0.000 claims description 18
238000012258 culturing Methods 0.000 claims description 18
230000000694 effects Effects 0.000 claims description 18
229910052742 iron Inorganic materials 0.000 claims description 17
239000000203 mixture Substances 0.000 claims description 17
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 16
230000004069 differentiation Effects 0.000 claims description 16
239000011159 matrix material Substances 0.000 claims description 16
239000003226 mitogen Substances 0.000 claims description 16
230000001413 cellular effect Effects 0.000 claims description 15
229960003957 dexamethasone Drugs 0.000 claims description 15
230000010261 cell growth Effects 0.000 claims description 14
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 14
241000282414 Homo sapiens Species 0.000 claims description 13
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 13
229940125396 insulin Drugs 0.000 claims description 12
239000011573 trace mineral Substances 0.000 claims description 12
235000013619 trace mineral Nutrition 0.000 claims description 12
108010035532 Collagen Proteins 0.000 claims description 11
102000008186 Collagen Human genes 0.000 claims description 11
229920001436 collagen Polymers 0.000 claims description 11
-1 nicotinamide, amino acids Chemical class 0.000 claims description 11
235000015097 nutrients Nutrition 0.000 claims description 11
229930182816 L-glutamine Natural products 0.000 claims description 10
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 10
235000011649 selenium Nutrition 0.000 claims description 10
229910052711 selenium Inorganic materials 0.000 claims description 10
239000011669 selenium Substances 0.000 claims description 10
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 9
210000004962 mammalian cell Anatomy 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 9
229960003104 ornithine Drugs 0.000 claims description 9
229920006395 saturated elastomer Polymers 0.000 claims description 9
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
102000004877 Insulin Human genes 0.000 claims description 8
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 8
229930064664 L-arginine Natural products 0.000 claims description 8
235000014852 L-arginine Nutrition 0.000 claims description 8
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 8
229940079593 drug Drugs 0.000 claims description 8
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 8
230000007774 longterm Effects 0.000 claims description 8
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 8
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 8
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical group OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 7
239000007995 HEPES buffer Substances 0.000 claims description 7
108090001061 Insulin Proteins 0.000 claims description 7
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 7
DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 7
108010054176 apotransferrin Proteins 0.000 claims description 7
239000000872 buffer Substances 0.000 claims description 7
230000006870 function Effects 0.000 claims description 7
210000003734 kidney Anatomy 0.000 claims description 7
229960002429 proline Drugs 0.000 claims description 7
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 7
239000004475 Arginine Substances 0.000 claims description 6
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 6
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 6
229940024606 amino acid Drugs 0.000 claims description 6
235000001014 amino acid Nutrition 0.000 claims description 6
239000003242 anti bacterial agent Substances 0.000 claims description 6
229940088710 antibiotic agent Drugs 0.000 claims description 6
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
235000009697 arginine Nutrition 0.000 claims description 6
150000001720 carbohydrates Chemical class 0.000 claims description 6
235000014633 carbohydrates Nutrition 0.000 claims description 6
239000008103 glucose Substances 0.000 claims description 6
VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims description 6
210000004153 islets of langerhan Anatomy 0.000 claims description 6
210000002966 serum Anatomy 0.000 claims description 6
239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 5
235000019743 Choline chloride Nutrition 0.000 claims description 5
229920002307 Dextran Polymers 0.000 claims description 5
229930182821 L-proline Natural products 0.000 claims description 5
108010085895 Laminin Proteins 0.000 claims description 5
102000007547 Laminin Human genes 0.000 claims description 5
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
229960003178 choline chloride Drugs 0.000 claims description 5
SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 5
229940088597 hormone Drugs 0.000 claims description 5
239000005556 hormone Substances 0.000 claims description 5
210000002490 intestinal epithelial cell Anatomy 0.000 claims description 5
XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical group NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 claims description 5
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 4
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 4
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
229930182555 Penicillin Natural products 0.000 claims description 4
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 4
239000012980 RPMI-1640 medium Substances 0.000 claims description 4
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 4
150000001413 amino acids Chemical class 0.000 claims description 4
235000010323 ascorbic acid Nutrition 0.000 claims description 4
229960005070 ascorbic acid Drugs 0.000 claims description 4
239000011668 ascorbic acid Substances 0.000 claims description 4
229960002685 biotin Drugs 0.000 claims description 4
235000020958 biotin Nutrition 0.000 claims description 4
239000011616 biotin Substances 0.000 claims description 4
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
108010045676 holotransferrin Proteins 0.000 claims description 4
229960000890 hydrocortisone Drugs 0.000 claims description 4
229940049954 penicillin Drugs 0.000 claims description 4
229940054269 sodium pyruvate Drugs 0.000 claims description 4
229960005322 streptomycin Drugs 0.000 claims description 4
238000002054 transplantation Methods 0.000 claims description 4
239000011701 zinc Substances 0.000 claims description 4
229910052725 zinc Inorganic materials 0.000 claims description 4
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 3
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 3
108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
239000004472 Lysine Substances 0.000 claims description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
102000013275 Somatomedins Human genes 0.000 claims description 3
102000009618 Transforming Growth Factors Human genes 0.000 claims description 3
108010009583 Transforming Growth Factors Proteins 0.000 claims description 3
229940087168 alpha tocopherol Drugs 0.000 claims description 3
244000309466 calf Species 0.000 claims description 3
FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 3
229910052802 copper Inorganic materials 0.000 claims description 3
239000010949 copper Substances 0.000 claims description 3
210000002919 epithelial cell Anatomy 0.000 claims description 3
210000002744 extracellular matrix Anatomy 0.000 claims description 3
235000010382 gamma-tocopherol Nutrition 0.000 claims description 3
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 3
229960004618 prednisone Drugs 0.000 claims description 3
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 3
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 3
229960003471 retinol Drugs 0.000 claims description 3
235000020944 retinol Nutrition 0.000 claims description 3
239000011607 retinol Substances 0.000 claims description 3
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 3
238000012360 testing method Methods 0.000 claims description 3
229960000984 tocofersolan Drugs 0.000 claims description 3
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 3
235000004835 α-tocopherol Nutrition 0.000 claims description 3
239000002076 α-tocopherol Substances 0.000 claims description 3
239000002478 γ-tocopherol Substances 0.000 claims description 3
QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 claims description 3
108091003079 Bovine Serum Albumin Proteins 0.000 claims description 2
102000004266 Collagen Type IV Human genes 0.000 claims description 2
108010042086 Collagen Type IV Proteins 0.000 claims description 2
AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 2
241000283073 Equus caballus Species 0.000 claims description 2
229910000608 Fe(NO3)3.9H2O Inorganic materials 0.000 claims description 2
108010067306 Fibronectins Proteins 0.000 claims description 2
102000016359 Fibronectins Human genes 0.000 claims description 2
239000004471 Glycine Substances 0.000 claims description 2
235000019766 L-Lysine Nutrition 0.000 claims description 2
FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
229930182844 L-isoleucine Natural products 0.000 claims description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
229930195722 L-methionine Natural products 0.000 claims description 2
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
239000004473 Threonine Substances 0.000 claims description 2
FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 2
150000001885 cortisol derivatives Chemical class 0.000 claims description 2
229960000304 folic acid Drugs 0.000 claims description 2
235000019152 folic acid Nutrition 0.000 claims description 2
239000011724 folic acid Substances 0.000 claims description 2
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 2
229960000310 isoleucine Drugs 0.000 claims description 2
229960003136 leucine Drugs 0.000 claims description 2
229960004452 methionine Drugs 0.000 claims description 2
QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 claims description 2
229960002477 riboflavin Drugs 0.000 claims description 2
235000019192 riboflavin Nutrition 0.000 claims description 2
239000002151 riboflavin Substances 0.000 claims description 2
229960001153 serine Drugs 0.000 claims description 2
229960003495 thiamine Drugs 0.000 claims description 2
229960002898 threonine Drugs 0.000 claims description 2
229960004799 tryptophan Drugs 0.000 claims description 2
229960004295 valine Drugs 0.000 claims description 2
229940011671 vitamin b6 Drugs 0.000 claims description 2
210000003668 pericyte Anatomy 0.000 claims 5
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 4
239000003862 glucocorticoid Substances 0.000 claims 3
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 2
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims 2
235000020661 alpha-linolenic acid Nutrition 0.000 claims 2
150000008064 anhydrides Chemical class 0.000 claims 2
238000011161 development Methods 0.000 claims 2
229930182830 galactose Natural products 0.000 claims 2
238000001802 infusion Methods 0.000 claims 2
229960004488 linolenic acid Drugs 0.000 claims 2
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims 2
239000007788 liquid Substances 0.000 claims 2
QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims 1
CZNVSLGYWMSMKE-OPDGVEILSA-K Ferric gluconate Chemical compound [Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O CZNVSLGYWMSMKE-OPDGVEILSA-K 0.000 claims 1
102000003745 Hepatocyte Growth Factor Human genes 0.000 claims 1
108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 1
108091006905 Human Serum Albumin Proteins 0.000 claims 1
102000008100 Human Serum Albumin Human genes 0.000 claims 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
102100037369 Nidogen-1 Human genes 0.000 claims 1
108010039918 Polylysine Proteins 0.000 claims 1
101000930457 Rattus norvegicus Albumin Proteins 0.000 claims 1
JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims 1
229930003779 Vitamin B12 Natural products 0.000 claims 1
FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 1
108010008217 nidogen Proteins 0.000 claims 1
108020004707 nucleic acids Proteins 0.000 claims 1
150000007523 nucleic acids Chemical class 0.000 claims 1
102000039446 nucleic acids Human genes 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
229920000656 polylysine Polymers 0.000 claims 1
229960005205 prednisolone Drugs 0.000 claims 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
FCHXJFJNDJXENQ-UHFFFAOYSA-N pyridoxal hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(C=O)=C1O FCHXJFJNDJXENQ-UHFFFAOYSA-N 0.000 claims 1
235000008160 pyridoxine Nutrition 0.000 claims 1
239000011677 pyridoxine Substances 0.000 claims 1
210000000813 small intestine Anatomy 0.000 claims 1
238000006467 substitution reaction Methods 0.000 claims 1
235000019157 thiamine Nutrition 0.000 claims 1
KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims 1
239000011721 thiamine Substances 0.000 claims 1
230000001131 transforming effect Effects 0.000 claims 1
235000019163 vitamin B12 Nutrition 0.000 claims 1
239000011715 vitamin B12 Substances 0.000 claims 1
101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 58
101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 58
101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 58
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 53
101800003838 Epidermal growth factor Proteins 0.000 description 51
229940116977 epidermal growth factor Drugs 0.000 description 51
230000002062 proliferating effect Effects 0.000 description 28
108020004999 messenger RNA Proteins 0.000 description 21
241000700159 Rattus Species 0.000 description 20
108020004414 DNA Proteins 0.000 description 18
108010082117 matrigel Proteins 0.000 description 16
230000006820 DNA synthesis Effects 0.000 description 13
210000000013 bile duct Anatomy 0.000 description 12
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 10
108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 9
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 9
239000000512 collagen gel Substances 0.000 description 8
238000002955 isolation Methods 0.000 description 8
230000002035 prolonged effect Effects 0.000 description 8
230000035899 viability Effects 0.000 description 8
102000029816 Collagenase Human genes 0.000 description 7
102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 7
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 7
238000000636 Northern blotting Methods 0.000 description 7
238000004113 cell culture Methods 0.000 description 7
229960002424 collagenase Drugs 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
239000007858 starting material Substances 0.000 description 7
108060005980 Collagenase Proteins 0.000 description 6
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 6
239000000654 additive Substances 0.000 description 6
229960001330 hydroxycarbamide Drugs 0.000 description 6
239000004615 ingredient Substances 0.000 description 6
239000012528 membrane Substances 0.000 description 6
210000003470 mitochondria Anatomy 0.000 description 6
229960003966 nicotinamide Drugs 0.000 description 6
235000005152 nicotinamide Nutrition 0.000 description 6
239000011570 nicotinamide Substances 0.000 description 6
102000012422 Collagen Type I Human genes 0.000 description 5
108010022452 Collagen Type I Proteins 0.000 description 5
108010052832 Cytochromes Proteins 0.000 description 5
102000018832 Cytochromes Human genes 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
239000007978 cacodylate buffer Substances 0.000 description 5
238000000576 coating method Methods 0.000 description 5
210000004379 membrane Anatomy 0.000 description 5
230000010412 perfusion Effects 0.000 description 5
230000010076 replication Effects 0.000 description 5
IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000000758 substrate Substances 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 4
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
229920002527 Glycogen Polymers 0.000 description 4
102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 4
108010066302 Keratin-19 Proteins 0.000 description 4
102000011782 Keratins Human genes 0.000 description 4
108010076876 Keratins Proteins 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
108090000901 Transferrin Proteins 0.000 description 4
102000004338 Transferrin Human genes 0.000 description 4
108010005774 beta-Galactosidase Proteins 0.000 description 4
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
229940096422 collagen type i Drugs 0.000 description 4
210000002472 endoplasmic reticulum Anatomy 0.000 description 4
239000000499 gel Substances 0.000 description 4
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
229940096919 glycogen Drugs 0.000 description 4
238000001000 micrograph Methods 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
238000011160 research Methods 0.000 description 4
229940104230 thymidine Drugs 0.000 description 4
239000012581 transferrin Substances 0.000 description 4
241001430294 unidentified retrovirus Species 0.000 description 4
102100023635 Alpha-fetoprotein Human genes 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
102000001301 EGF receptor Human genes 0.000 description 3
108060006698 EGF receptor Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
102000003972 Fibroblast growth factor 7 Human genes 0.000 description 3
108090000385 Fibroblast growth factor 7 Proteins 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
241001529936 Murinae Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
108010006886 Vitrogen Proteins 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
230000007423 decrease Effects 0.000 description 3
230000002950 deficient Effects 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
239000010410 layer Substances 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
239000003550 marker Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
230000002297 mitogenic effect Effects 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
230000008929 regeneration Effects 0.000 description 3
238000011069 regeneration method Methods 0.000 description 3
239000002356 single layer Substances 0.000 description 3
238000010186 staining Methods 0.000 description 3
210000000130 stem cell Anatomy 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
238000001890 transfection Methods 0.000 description 3
230000007704 transition Effects 0.000 description 3
229940088594 vitamin Drugs 0.000 description 3
229930003231 vitamin Natural products 0.000 description 3
235000013343 vitamin Nutrition 0.000 description 3
239000011782 vitamin Substances 0.000 description 3
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
229930182566 Gentamicin Natural products 0.000 description 2
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 2
101710184069 Hepatocyte growth factor receptor Proteins 0.000 description 2
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
102000005936 beta-Galactosidase Human genes 0.000 description 2
210000000941 bile Anatomy 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
230000036267 drug metabolism Effects 0.000 description 2
238000003255 drug test Methods 0.000 description 2
238000000635 electron micrograph Methods 0.000 description 2
238000001493 electron microscopy Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
229960005542 ethidium bromide Drugs 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
229960002518 gentamicin Drugs 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
230000006698 induction Effects 0.000 description 2
210000003963 intermediate filament Anatomy 0.000 description 2
210000005228 liver tissue Anatomy 0.000 description 2
230000037353 metabolic pathway Effects 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
230000007886 mutagenicity Effects 0.000 description 2
231100000299 mutagenicity Toxicity 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
210000002824 peroxisome Anatomy 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
241000894007 species Species 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
238000004627 transmission electron microscopy Methods 0.000 description 2
238000011282 treatment Methods 0.000 description 2
229960005356 urokinase Drugs 0.000 description 2
239000001149 (9Z,12Z)-octadeca-9,12-dienoate Substances 0.000 description 1
WTTJVINHCBCLGX-UHFFFAOYSA-N (9trans,12cis)-methyl linoleate Natural products CCCCCC=CCC=CCCCCCCCC(=O)OC WTTJVINHCBCLGX-UHFFFAOYSA-N 0.000 description 1
108020005096 28S Ribosomal RNA Proteins 0.000 description 1
LNJCGNRKWOHFFV-UHFFFAOYSA-N 3-(2-hydroxyethylsulfanyl)propanenitrile Chemical compound OCCSCCC#N LNJCGNRKWOHFFV-UHFFFAOYSA-N 0.000 description 1
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000282465 Canis Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
206010057573 Chronic hepatic failure Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
102000003849 Cytochrome P450 Human genes 0.000 description 1
102100038739 Cytochrome P450 2B6 Human genes 0.000 description 1
CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
208000010334 End Stage Liver Disease Diseases 0.000 description 1
108700039887 Essential Genes Proteins 0.000 description 1
108010003471 Fetal Proteins Proteins 0.000 description 1
102000004641 Fetal Proteins Human genes 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
101000957383 Homo sapiens Cytochrome P450 2B6 Proteins 0.000 description 1
101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 1
102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 1
108010066321 Keratin-14 Proteins 0.000 description 1
102000018329 Keratin-18 Human genes 0.000 description 1
108010066327 Keratin-18 Proteins 0.000 description 1
108010070511 Keratin-8 Proteins 0.000 description 1
QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
239000004201 L-cysteine Substances 0.000 description 1
235000013878 L-cysteine Nutrition 0.000 description 1
239000004158 L-cystine Substances 0.000 description 1
235000019393 L-cystine Nutrition 0.000 description 1
239000004395 L-leucine Substances 0.000 description 1
235000019454 L-leucine Nutrition 0.000 description 1
241000208202 Linaceae Species 0.000 description 1
235000004431 Linum usitatissimum Nutrition 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
PKIXXJPMNDDDOS-UHFFFAOYSA-N Methyl linoleate Natural products CCCCC=CCCC=CCCCCCCCC(=O)OC PKIXXJPMNDDDOS-UHFFFAOYSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
101150053185 P450 gene Proteins 0.000 description 1
241001504519 Papio ursinus Species 0.000 description 1
102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
230000018199 S phase Effects 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108010033576 Transferrin Receptors Proteins 0.000 description 1
102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
LUTSRLYCMSCGCS-BWOMAWGNSA-N [(3s,8r,9s,10r,13s)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,16-decahydrocyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC=C3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 LUTSRLYCMSCGCS-BWOMAWGNSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
229960003767 alanine Drugs 0.000 description 1
108010026331 alpha-Fetoproteins Proteins 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
101150010487 are gene Proteins 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
229960005261 aspartic acid Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
229950004398 broxuridine Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000012592 cell culture supplement Substances 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000007705 chemical test Methods 0.000 description 1
238000013098 chemical test method Methods 0.000 description 1
208000011444 chronic liver failure Diseases 0.000 description 1
238000003501 co-culture Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
210000004395 cytoplasmic granule Anatomy 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000000326 densiometry Methods 0.000 description 1
210000001047 desmosome Anatomy 0.000 description 1
238000001784 detoxification Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000004626 essential fatty acids Nutrition 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
238000010195 expression analysis Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000004744 fabric Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000003633 gene expression assay Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000004190 glucose uptake Effects 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
210000004024 hepatic stellate cell Anatomy 0.000 description 1
229960002885 histidine Drugs 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000028993 immune response Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940124589 immunosuppressive drug Drugs 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
235000018977 lysine Nutrition 0.000 description 1
210000003712 lysosome Anatomy 0.000 description 1
230000001868 lysosomic effect Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
231100000989 no adverse effect Toxicity 0.000 description 1
230000006911 nucleation Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
230000005305 organ development Effects 0.000 description 1
239000002357 osmotic agent Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
210000004738 parenchymal cell Anatomy 0.000 description 1
238000012753 partial hepatectomy Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
229960005190 phenylalanine Drugs 0.000 description 1
239000004033 plastic Substances 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
210000004258 portal system Anatomy 0.000 description 1
230000035409 positive regulation of cell proliferation Effects 0.000 description 1
238000005381 potential energy Methods 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
229960003581 pyridoxal Drugs 0.000 description 1
235000008164 pyridoxal Nutrition 0.000 description 1
239000011674 pyridoxal Substances 0.000 description 1
RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
239000011764 pyridoxine hydrochloride Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
229960000342 retinol acetate Drugs 0.000 description 1
QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
235000019173 retinyl acetate Nutrition 0.000 description 1
239000011770 retinyl acetate Substances 0.000 description 1
210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
239000000523 sample Substances 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
229960004441 tyrosine Drugs 0.000 description 1
230000004143 urea cycle Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
235000012711 vitamin K3 Nutrition 0.000 description 1
239000011652 vitamin K3 Substances 0.000 description 1
229940041603 vitamin k 3 Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5067—Liver cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/12—Hepatocyte growth factor [HGF]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/148—Transforming growth factor alpha [TGF-a]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Organic Chemistry (AREA)
Toxicology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Zoology (AREA)
Food Science & Technology (AREA)
Wood Science & Technology (AREA)
Tropical Medicine & Parasitology (AREA)
Gastroenterology & Hepatology (AREA)
General Engineering & Computer Science (AREA)
Endocrinology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Apparatus Associated With Microorganisms And Enzymes (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

BG102837A 1996-03-18 1998-10-12 Среда за култивиране на клетки от бозайници BG102837A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/617,325 US6043092A (en)	1996-03-18	1996-03-18	Cell culture media for mammalian cells
PCT/US1997/003880 WO1997034999A1 (en)	1996-03-18	1997-03-12	Cell culture media for mammalian cells

Publications (1)

Publication Number	Publication Date
BG102837A true BG102837A (bg)	1999-05-31

Family

ID=24473190

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG102837A BG102837A (bg)	1996-03-18	1998-10-12	Среда за култивиране на клетки от бозайници

Country Status (18)

Country	Link
US (5)	US6043092A (de)
EP (1)	EP0929662B1 (de)
KR (1)	KR20000064667A (de)
CN (1)	CN1217745A (de)
AT (1)	ATE343629T1 (de)
AU (1)	AU733373B2 (de)
BG (1)	BG102837A (de)
BR (1)	BR9708105A (de)
CA (1)	CA2249289A1 (de)
CZ (1)	CZ297198A3 (de)
DE (1)	DE69736861D1 (de)
EA (1)	EA199800835A1 (de)
IL (1)	IL126273A0 (de)
NO (1)	NO984314L (de)
NZ (1)	NZ331935A (de)
PL (1)	PL328922A1 (de)
TR (1)	TR199801859T2 (de)
WO (1)	WO1997034999A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0891419A4 (de)	1996-03-12	2000-03-01	Life Technologies Inc	Nährstoffzusatz für hematopoetische zellkulturen
AU4330597A (en)	1996-08-30	1998-03-19	Life Technologies, Inc.	Serum-free mammalian cell culture medium, and uses thereof
US6692961B1 (en)	1996-10-11	2004-02-17	Invitrogen Corporation	Defined systems for epithelial cell culture and use thereof
WO2000018885A1 (en)	1998-09-29	2000-04-06	Gamida Cell Ltd.	Methods of controlling proliferation and differentiation of stem and progenitor cells
EP0953633A1 (de) *	1998-04-28	1999-11-03	Livercell L.L.C.	Zellkulturverfahren und Medium zur Herstellung von vermehrungsfähige, normale, differenzierte Humane Leberzellen
JP3553858B2 (ja) *	1999-08-25	2004-08-11	東洋紡績株式会社	血管網類似構造体を有する細胞培養用モジュール
US6767741B1 (en)	1999-08-27	2004-07-27	Invitrogen Corporation	Metal binding compounds and their use in cell culture medium compositions
DE60037819T2 (de) *	1999-08-27	2009-01-08	Invitrogen Corp., Carlsbad	Metallbindende verbindungen und deren verwendung in zusammensetzungen für zellkulturmedien
IL136232A0 (en) *	2000-05-18	2001-05-20	Bar Ilan University Res Author	Measurements of enzymatic activity in a single, individual cell in population
EP1291415A4 (de) *	2000-06-01	2004-07-14	Hokkaido Tech Licensing Office	Methode zur herstellung von kleinen hepatozyten welche im gefriergetrockneten zustand haltbar sind und die entsprechende methode
US6762053B2 (en) *	2000-06-09	2004-07-13	Vitrolife, Inc.	Mammalian gamete and embryo culture media and culture media supplements
AU2002214304A1 (en) *	2000-11-17	2002-05-27	Takeda Chemical Industries Ltd.	Method for estimating metabolic function of xenobiotic and induction thereof
US6506576B2 (en)	2001-03-14	2003-01-14	Board Of Trustees Of The University Of Arkansas	Serum-and steroid-free culture media for cerebellar granule neurons
US20040152095A1 (en) *	2001-05-16	2004-08-05	Naoki Tanimizu	Method of detecting and seperating of undifferentiated liver cellss using dlk
EP1321515A1 (de) *	2001-12-21	2003-06-25	Ingenium Pharmaceuticals AG	Zellkulturverfahren
IL152904A0 (en) *	2002-01-24	2003-06-24	Gamida Cell Ltd	Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062404A1 (en)	2002-01-25	2003-07-31	Gamida-Cell Ltd.	Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
WO2003078567A2 (en) *	2002-03-18	2003-09-25	Gamida-Cell Ltd.	Methods of inducing differentiation in ex vivo expanded stem cells
TWI288779B (en) *	2002-03-28	2007-10-21	Blasticon Biotech Forschung	Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
HK1080111A1 (zh) *	2002-03-29	2006-04-21	新加坡眼部研究所	为研究、临床眼晴表面移植和组织工程的应用而生长人类结膜组织等同物的方法
CA2481953A1 (en) *	2002-04-04	2003-10-16	Daiichi Pure Chemicals Co., Ltd.	Method of culturing liver cells over long time
WO2003102171A1 (en) *	2002-05-28	2003-12-11	Becton, Dickinson And Company	Expansion and transdifferentiation of human acinar cells
US20050054097A1 (en) *	2002-11-17	2005-03-10	Tony Peled	EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
MXPA05006522A (es) *	2002-12-23	2006-02-17	Bristol Myers Squibb Co	Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina.
IL154677A0 (en) *	2003-02-27	2003-09-17	Univ Bar Ilan	A method and apparatus for manipulating an individual cell
US20050054103A1 (en) *	2003-03-07	2005-03-10	Tony Peled	Expansion of renewable stem cell populations using modulators of PI 3-kinase
US20040229355A1 (en) *	2003-05-14	2004-11-18	Board Of Regents University Of Texas System	Culture medium for long-term culture of hepatocytes
EP2340856B2 (de) *	2003-05-24	2017-11-15	La Prairie Group AG	Kosmetische oder dermatologische Zubereitung umfassend eine Nährmedienphase
US8597597B2 (en)	2003-06-26	2013-12-03	Seng Enterprises Ltd.	Picoliter well holding device and method of making the same
US7888110B2 (en)	2003-06-26	2011-02-15	Seng Enterprises Ltd.	Pico liter well holding device and method of making the same
US9200245B2 (en)	2003-06-26	2015-12-01	Seng Enterprises Ltd.	Multiwell plate
WO2005005608A2 (en) *	2003-06-30	2005-01-20	Lifescan, Inc.	Compositions and methods for differentiating adipose stromal cells into pancratic beta cells
WO2005008626A1 (en) *	2003-07-11	2005-01-27	University Of North Carolina At Chapel Hill	Methods and systems for controlling a computer using a video image and for combining the video image with a computer desktop
US20050064524A1 (en) *	2003-08-11	2005-03-24	Mordechai Deutsch	Population of cells utilizable for substance detection and methods and devices using same
JP4657108B2 (ja) *	2003-12-26	2011-03-23	美保古江	Ｅｓ細胞培養用基礎培地
WO2005074893A1 (en) *	2004-02-03	2005-08-18	Chemagis Ltd.	Stable amorphous forms of montelukast sodium
EP1609462B1 (de) *	2004-04-22	2015-07-29	La Prairie Group AG	Kosmetische oder dermatologische Zubereitung umfassend eine Nährmedienphase
KR20060000547A (ko) *	2004-06-29	2006-01-06	라이프코드인터내셔날 주식회사	대량의 간세포 배양 및 간세포 구상체 형성용 고농도 배지
US7403647B2 (en) *	2004-09-13	2008-07-22	Seng Enterprises Ltd.	Method for identifying an image of a well in an image of a well-bearing component
WO2006030442A2 (en)	2004-09-16	2006-03-23	Gamida-Cell Ltd.	Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
DE602005023534D1 (de)	2005-01-25	2010-10-21	Seng Entpr Ltd	Mikrofluidische vorrichtung zur untersuchung zellen
US7409239B2 (en) *	2005-05-05	2008-08-05	The Hong Kong Polytechnic University	Method for predicting the blood glucose level of a person
US20070128685A1 (en) *	2005-07-01	2007-06-07	Rodolfo Faudoa	Methods and compositions for cell culture
DE102005031532A1 (de) *	2005-07-01	2007-01-04	Cytonet Gmbh & Co. Kg	Lagermedium für Zellen
US20070003541A1 (en) *	2005-07-01	2007-01-04	Rodolfo Faudoa	Methods and compositions for therapeutics
US20070004036A1 (en) *	2005-07-01	2007-01-04	Rodolfo Faudoa	Methods and compositions for keratinocyte culture
WO2007044418A2 (en) *	2005-10-06	2007-04-19	Moscatello David K	Cell culture media, kits and methods of use
US8288120B2 (en)	2005-11-03	2012-10-16	Seng Enterprises Ltd.	Method for studying floating, living cells
US8846393B2 (en) *	2005-11-29	2014-09-30	Gamida-Cell Ltd.	Methods of improving stem cell homing and engraftment
US20070231901A1 (en) *	2005-12-02	2007-10-04	Shuichi Takayama	Microfluidic cell culture media
US20090004159A1 (en) *	2006-01-24	2009-01-01	The Board Of Trustees Of The University Of Illinoi	Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
US20070196810A1 (en) *	2006-01-24	2007-08-23	Northfield Laboratories Inc.	Polymerized Hemoglobin Media and its Use in Isolation and Transplantation of Islet Cells
US20060223999A1 (en) *	2006-05-10	2006-10-05	Chemagis Ltd.	Process for preparing montelukast and precursors thereof
US9145540B1 (en)	2007-11-15	2015-09-29	Seng Enterprises Ltd.	Device for the study of living cells
US20090190135A1 (en) *	2007-11-28	2009-07-30	University Of Massachusetts Lowell	CELL CULTURE HYDROGEL WITH pH INDICATOR
EP2237887A2 (de)	2007-12-26	2010-10-13	Seng Enterprises Ltd.	Vorrichtung zur untersuchung von lebenden zellen
EP2412800A1 (de)	2010-07-29	2012-02-01	Koninklijke Nederlandse Akademie van Wetenschappen	Leberorganoid, Verwendungen davon und Kultivierungsverfahren zum Erhalten davon
EP2393917B1 (de)	2009-02-03	2016-04-06	Koninklijke Nederlandse Akademie van Wetenschappen	Kulturboden für epithelstammzellen und organellen, die diese stammzellen umfassen
KR101775000B1 (ko) *	2009-06-26	2017-09-04	노보 노르디스크 에이/에스	인슐린, 니코틴아미드 및 아미노산을 포함하는 제제
WO2011022045A2 (en) *	2009-08-17	2011-02-24	Singh Ashok K	Apparatus and process for generating and harvesting adult stem cells and fluid associated with it from skin and omentum for medical, cosmetic, and veterinary use
CN102344904B (zh) *	2010-08-02	2014-04-30	深圳华大基因科技有限公司	一种猪细胞培养基
WO2012092542A2 (en)	2010-12-30	2012-07-05	University Of Massachusetts Lowell	Responsive cell culture hydrogel
CN102399742B (zh) *	2011-09-30	2014-07-30	东莞中山大学研究院	用于哺乳动物唾液腺上皮细胞和唾液腺干细胞培养的无血清培养液
HK1202581A1 (en)	2012-02-13	2015-10-02	Gamida-Cell Ltd.	Mesenchymal stem cells conditioned medium and methods of generating and using the same
US9493744B2 (en)	2012-06-20	2016-11-15	Genentech, Inc.	Methods for viral inactivation and other adventitious agents
US9175266B2 (en)	2012-07-23	2015-11-03	Gamida Cell Ltd.	Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en)	2012-07-23	2017-02-14	Gamida Cell Ltd.	Methods of culturing and expanding mesenchymal stem cells
WO2014082685A1 (en) *	2012-11-30	2014-06-05	Swiss Stem Cell Foundation	Serum-free medium for human mesenchymal stem cells
AR095196A1 (es)	2013-03-15	2015-09-30	Regeneron Pharma	Medio de cultivo celular libre de suero
TR201815058T4 (tr)	2014-07-11	2018-11-21	Grifols Worldwide Operations Ltd	Hi̇poksi̇ i̇le i̇ndüklenen faktör (hif) i̇le i̇lgi̇li̇ nörodejenerati̇f bozukluklarin tedavi̇si̇nde kullanilmak üzere transferri̇n.
CN106318998B (zh) *	2015-07-08	2019-08-20	浙江海正博锐生物制药有限公司	用于提高重组人ⅱ型肿瘤坏死因子受体-抗体融合蛋白唾液酸化水平的组合物
TWI870789B (zh)	2015-08-04	2025-01-21	美商再生元醫藥公司	補充牛磺酸之細胞培養基及用法
CN108925137A (zh)	2016-02-22	2018-11-30	新加坡科技研究局	细胞培养基
GB201721615D0 (en)	2017-12-21	2018-02-07	Koninklijke Nederlandse Akademie Van Wetenschappen	Immune cell organoid co-cultures
CA3102627A1 (en) *	2018-06-18	2019-12-26	Oakbio, Inc.	Methods for producing rich cell culture media using chemoautotrophic microbes
US20220290097A1 (en) *	2019-08-03	2022-09-15	Shenzhen Mytang Biotechnology Co., Ltd.	Poultry Egg-Based Culture Medium
US12297451B1 (en)	2019-10-25	2025-05-13	Regeneron Pharmaceuticals, Inc.	Cell culture medium
CN115369087B (zh) *	2021-05-17	2024-02-09	合肥中科普瑞昇生物医药科技有限公司	肝癌原代细胞的培养基及培养方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4439521A (en) *	1981-10-21	1984-03-27	Ontario Cancer Institute	Method for producing self-reproducing mammalian pancreatic islet-like structures
FR2543158B1 (fr) *	1983-03-24	1985-11-15	Inst Nat Sante Rech Med	Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
US4902295A (en) *	1985-08-26	1990-02-20	Hana Biologics, Inc.	Transplantable artificial tissue
NO162160C (no) *	1987-01-09	1989-11-15	Medi Cult As	Serumfritt vekstmedium, samt anvendelse derav.
DE3711699A1 (de) *	1987-04-07	1988-11-10	Fraunhofer Ges Forschung	Medium zur kultivierung und proliferation von epithelialen zelltypen
US5529920A (en) *	1988-12-14	1996-06-25	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Human liver epithelial cell line and culture media therefor
AU621972B2 (en) *	1988-12-14	1992-03-26	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	Cell culture medium for human liver epithelial cell line
US5380660A (en) *	1989-02-02	1995-01-10	New England Medical Center Hospitals, Inc.	Method of treating serum or serum-containing medium to inactivate an inhibitor of hepatocyte differentiation
EP0449445A3 (en) *	1990-03-27	1993-08-25	Pfizer Inc.	Preparation of beta-ketoesters useful in preparing quinolone antibiotics
JPH0728732B2 (ja) *	1990-04-17	1995-04-05	日本石油株式会社	動物細胞増殖促進剤及び無血清培地
US5122469A (en) *	1990-10-03	1992-06-16	Genentech, Inc.	Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0605428B9 (de) *	1991-06-24	2003-01-02	hCell Technology, Inc.	In langzeitkultur gehaltene hormon-absondernde pankreatische zellen
US5116753A (en) *	1991-07-30	1992-05-26	The Salk Institute For Biological Studies	Maintenance of pancreatic islets
WO1993003142A1 (en) *	1991-08-07	1993-02-18	Albert Einstein College Of Medicine	Proliferation of hepatocyte precursors
ES2157225T3 (es) *	1992-10-09	2001-08-16	Advanced Tissue Sciences Inc	Celulas hepaticas de reserva.
US5405772A (en) *	1993-06-18	1995-04-11	Amgen Inc.	Medium for long-term proliferation and development of cells
US5587309A (en) *	1994-04-29	1996-12-24	The United States Of America As Represented By The Department Of Health And Human Services	Method of stimulating proliferation and differentiation of human fetal pancreatic cells ex vivo
US5695998A (en) *	1995-02-10	1997-12-09	Purdue Research Foundation	Submucosa as a growth substrate for islet cells

1996
- 1996-03-18 US US08/617,325 patent/US6043092A/en not_active Expired - Lifetime
1997
- 1997-03-12 PL PL97328922A patent/PL328922A1/xx unknown
- 1997-03-12 IL IL12627397A patent/IL126273A0/xx unknown
- 1997-03-12 CN CN97194385A patent/CN1217745A/zh active Pending
- 1997-03-12 AU AU25287/97A patent/AU733373B2/en not_active Ceased
- 1997-03-12 CZ CZ982971A patent/CZ297198A3/cs unknown
- 1997-03-12 CA CA002249289A patent/CA2249289A1/en not_active Abandoned
- 1997-03-12 TR TR1998/01859T patent/TR199801859T2/xx unknown
- 1997-03-12 KR KR1019980707383A patent/KR20000064667A/ko not_active Withdrawn
- 1997-03-12 BR BR9708105-1A patent/BR9708105A/pt not_active Application Discontinuation
- 1997-03-12 EA EA199800835A patent/EA199800835A1/ru unknown
- 1997-03-12 NZ NZ331935A patent/NZ331935A/xx unknown
- 1997-03-12 WO PCT/US1997/003880 patent/WO1997034999A1/en not_active Ceased
- 1997-03-12 AT AT97916744T patent/ATE343629T1/de not_active IP Right Cessation
- 1997-03-12 DE DE69736861T patent/DE69736861D1/de not_active Expired - Lifetime
- 1997-03-12 EP EP97916744A patent/EP0929662B1/de not_active Expired - Lifetime
1998
- 1998-09-17 NO NO984314A patent/NO984314L/no not_active Application Discontinuation
- 1998-10-12 BG BG102837A patent/BG102837A/bg unknown
1999
- 1999-03-12 US US09/267,551 patent/US6413772B1/en not_active Expired - Fee Related
2002
- 2002-02-12 US US10/075,048 patent/US6670180B2/en not_active Expired - Fee Related
2003
- 2003-11-25 US US10/722,378 patent/US7022520B2/en not_active Expired - Fee Related
2006
- 2006-02-14 US US11/353,453 patent/US20060141447A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PL328922A1 (en)	1999-03-01
EA199800835A1 (ru)	1999-02-25
ATE343629T1 (de)	2006-11-15
CZ297198A3 (cs)	1999-03-17
EP0929662A1 (de)	1999-07-21
US20060141447A1 (en)	2006-06-29
NO984314L (no)	1998-11-17
US6670180B2 (en)	2003-12-30
US7022520B2 (en)	2006-04-04
KR20000064667A (ko)	2000-11-06
TR199801859T2 (xx)	1999-02-22
WO1997034999A1 (en)	1997-09-25
US20020155603A1 (en)	2002-10-24
CN1217745A (zh)	1999-05-26
US6043092A (en)	2000-03-28
DE69736861D1 (de)	2006-12-07
US6413772B1 (en)	2002-07-02
AU2528797A (en)	1997-10-10
IL126273A0 (en)	1999-05-09
EP0929662A4 (de)	2002-12-04
NO984314D0 (no)	1998-09-17
EP0929662B1 (de)	2006-10-25
BR9708105A (pt)	2000-01-04
US20040166579A1 (en)	2004-08-26
CA2249289A1 (en)	1997-09-25
NZ331935A (en)	2000-05-26
AU733373B2 (en)	2001-05-10

Publication	Publication Date	Title
BG102837A (bg)	1999-05-31	Среда за култивиране на клетки от бозайници
US5712159A (en)	1998-01-27	Glucose responsive insulin secreting β-cell lines and method for producing same
US6692961B1 (en)	2004-02-17	Defined systems for epithelial cell culture and use thereof
Ambesi-Impiombato et al.	1979	Thyroid cells in culture
US7217570B2 (en)	2007-05-15	Organotypic intestinal culture and methods of use thereof
Romijn	1988	Development and advantages of serum‐free, chemically defined nutrient media for culturing of nerve tissue
Brandi et al.	1986	Bovine parathyroid cells: cultures maintained for more than 140 population doublings.
WO2005085422A9 (en)	2006-06-22	Adult stem cells and uses thereof
JP2009106301A (ja)	2009-05-21	ヒトｃｎｓ神経幹細胞の培養
JP2004121258A (ja)	2004-04-22	神経芽細胞の産生方法
O'malley et al.	1991	Local support cells promote survival of substantia nigra dopaminergic neurons in culture
Takigawa et al.	1991	Establishment from a human chondrosarcoma of a new immortal cell line with high tumorigenicity in vivo, which is able to form proteoglycan‐rich cartilage‐like nodules and to respond to insulin in vitro
CA2537462A1 (en)	2005-03-31	Cell culture media comprising fructose as the primary energy source
BR112012009848B1 (pt)	2021-11-03	Método de obtenção de células-tronco/progenitoras multipotentes de mamíferos capazes de se diferenciar em linhagens hepáticas e pancreáticas
Hoffmann et al.	1989	Proliferation of fetal rat hepatocytes in response to growth factors and hormones in primary culture
JP2016515403A (ja)	2016-05-30	ニューロン細胞培養のための培地組成物
RU2333243C2 (ru)	2008-09-10	Дедифференцированные программируемые стволовые клетки моноцитарного происхождения и их получение и применение
Rizzino et al.	1980	The effects of laminin on the growth and differentiation of embryonal carcinoma cells in defined media
US12584110B2 (en)	2026-03-24	Functional feline pancreatic cells from adipose tissue
WO1997016536A1 (en)	1997-05-09	Method for ex vivo proliferation and differentiation of adult pancreatic islet cells, media useful therefor and uses thereof
Toda et al.	1993	Plural cells organize thyroid follicles through aggregation and linkage in collagen gel culture of porcine follicle cells
US6008047A (en)	1999-12-28	Cell culturing method and medium
JP2003530103A5 (de)	2006-08-03
JP2000512128A (ja)	2000-09-19	哺乳類細胞用の細胞培養培地
EP1059352A1 (de)	2000-12-13	Langzeitkultur humaner Karzinome